The ROC 'n' role of the multiplex assay for early detection of ovarian cancer

Nature Clinical Practice Oncology

Volumn 5, Issue 10, 2008, Pages 568-569

  Nick, Alpa M ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; OSTEOPONTIN; PROLACTIN; SOMATOMEDIN B;

BIOASSAY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TREATMENT RESPONSE;

EID: 53749092959     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1214     Document Type: Short Survey

References (8)

1. Jemal A et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96
2. Gagnon A and Ye B (2008) Discovery and application of protein biomarkers for ovarian cancer. Curr Opin Obstet Gynecol 20: 9-13
3. Høgdall E (2008) Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 20: 4-8
4. Bast RC Jr et al. (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15 (Suppl 3): S274-S281
5. Jacobs I et al. (1988) Multimodal approach to screening for ovarian cancer. Lancet 1: 268-271
6. Moore RG et al. (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108: 402-408
7. Visintin I et al. (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065-1072
8. Mor G et al. (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 102: 7677-7682